Rubio Mercedes, Bassat Quique, Estivill Xavier, Mayor Alfredo
ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Carrer Rosselló 153 (CEK building), 08036, Barcelona, Spain.
Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique.
Malar J. 2016 Mar 15;15:167. doi: 10.1186/s12936-016-1222-9.
Symptoms caused by bacterial, viral and malarial infections usually overlap and aetiologic diagnosis is difficult. Patient management in low-resource countries with limited laboratory services has been based predominantly on clinical evaluation and syndromic approaches. However, such clinical assessment has limited accuracy both for identifying the likely aetiological cause and for the early recognition of patients who will progress to serious or fatal disease. Plasma-detectable biomarkers that rapidly and accurately diagnose severe infectious diseases could reduce morbidity and decrease the unnecessary use of usually scarce therapeutic drugs. The discovery of microRNAs (miRNAs) has opened exciting new avenues to identify blood biomarkers of organ-specific injury. This review assesses current knowledge on the relationship between malaria disease and miRNAs, and evaluates how future research might lead to the use of these small molecules for identifying patients with severe malaria disease and facilitate treatment decisions.
由细菌、病毒和疟疾感染引起的症状通常相互重叠，病因诊断困难。在实验室服务有限的资源匮乏国家，患者管理主要基于临床评估和综合征方法。然而，这种临床评估在确定可能的病因以及早期识别将发展为严重或致命疾病的患者方面准确性有限。能够快速准确诊断严重传染病的血浆可检测生物标志物可以降低发病率，并减少通常稀缺的治疗药物的不必要使用。微小RNA（miRNA）的发现为识别器官特异性损伤的血液生物标志物开辟了令人兴奋的新途径。本综述评估了关于疟疾疾病与miRNA之间关系的现有知识，并评估了未来的研究如何可能导致使用这些小分子来识别重症疟疾患者并促进治疗决策。
